Galli Francesco, Lee Rosalind, Atkinson Jeffrey, Floridi Ardesio, Kelly Frank J
Lung Biology, School of Health and Life Sciences, King's College, London, UK.
Free Radic Res. 2003 Nov;37(11):1225-33. doi: 10.1080/10715760310001604125.
The uptake and biotransformation of gamma-tocopherol (gamma-T) in humans is largely unknown. Using a stable isotope method we investigated these aspects of gamma-T biology in healthy volunteers and their response to gamma-T supplementation.
A single bolus of 100 mg of deuterium labeled gamma-T acetate (d(2)-gamma-TAC, 94% isotopic purity) was administered with a standard meal to 21 healthy subjects. Blood and urine (first morning void) were collected at baseline and a range of time points between 6 and 240 h post-supplemetation. The concentrations of d(2) and d(0)-gamma-T in plasma and its major metabolite 2,7,8-trimethyl-2-(b-carboxyethyl)-6-hydroxychroman (-gamma-CEHC) in plasma and urine were measured by GC-MS. In two subjects, the total urine volume was collected for 72 h post-supplementation. The effects of gamma-T supplementation on alpha-T concentrations in plasma and alpha-T and gamma-T metabolite formation were also assessed by HPLC or GC-MS analysis.
At baseline, mean plasma alpha-T concentration was approximately 15 times higher than gamma-T (28.3 vs. 1.9 micromol/l). In contrast, plasma gamma-CEHC concentration (0.191 micromol/l) was 12 fold greater than alpha-CEHC (0.016 micromol/l) while in urine it was 3.5 fold lower (0.82 and 2.87 micromol, respectively) suggesting that the clearance of alpha-CEHC from plasma was more than 40 times that of gamma-CEHC. After d(2)-gamma-TAC administration, the d(2) forms of gamma-T and gamma-CEHC in plasma and urine increased, but with marked inter-individual variability, while the d(0) species were hardly affected. Mean total concentrations of gamma-T and gamma-CEHC in plasma and urine peaked, respectively, between 0-9, 6-12 and 9-24 h post-supplementation with increases over baseline levels of 6-14 fold. All these parameters returned to baseline by 72 h. Following challenge, the total urinary excretion of d(2)-gamma-T equivalents was approximately 7 mg. Baseline levels of gamma-T correlated positively with the post-supplementation rise of (d(0) + d(2)) - gamma - T and gamma-CEHC levels in plasma, but correlated negatively with urinary levels of (d(0) + d(2))-gamma-CEHC. Supplementation with 100 mg gamma-TAC had minimal influence on plasma concentrations of alpha-T and alpha-T-related metabolite formation and excretion.
Ingestion of 100mg of gamma-TAC transiently increases plasma concentrations of gamma-T as it undergoes sustained catabolism to CEHC without markedly influencing the pre-existing plasma pool of gamma-T nor the concentration and metabolism of alpha-T. These pathways appear tightly regulated, most probably to keep high steady-state blood ratios alpha-T to gamma-T and gamma-CEHC to alpha-CEHC.
人体中γ-生育酚(γ-T)的摄取和生物转化情况在很大程度上尚不明确。我们采用稳定同位素方法,对健康志愿者体内γ-T生物学的这些方面及其对γ-T补充剂的反应进行了研究。
给21名健康受试者随标准餐服用单次剂量100mg的氘标记γ-生育酚乙酸酯(d(2)-γ-TAC,同位素纯度94%)。在基线以及补充后6至240小时的一系列时间点采集血液和尿液(晨尿)。通过气相色谱 - 质谱法(GC-MS)测定血浆中d(2)和d(0)-γ-T的浓度以及血浆和尿液中其主要代谢产物2,7,8-三甲基-2-(β-羧乙基)-6-羟基色满(-γ-CEHC)的浓度。在两名受试者中,补充后72小时收集全部尿量。还通过高效液相色谱法(HPLC)或GC-MS分析评估了γ-T补充剂对血浆中α-T浓度以及α-T和γ-T代谢产物形成的影响。
在基线时,血浆中α-T的平均浓度比γ-T高约15倍(28.3对1.9微摩尔/升)。相比之下,血浆中γ-CEHC浓度(0.191微摩尔/升)比α-CEHC(0.016微摩尔/升)高12倍,而在尿液中则低3.5倍(分别为0.82和2.87微摩尔),这表明α-CEHC从血浆中的清除率比γ-CEHC高40多倍。给予d(2)-γ-TAC后,血浆和尿液中γ-T和γ-CEHC的d(2)形式增加,但个体间差异显著,而d(0)形式几乎未受影响。血浆和尿液中γ-T和γ-CEHC的平均总浓度分别在补充后0 - 9、6 - 12和9 - 24小时达到峰值,比基线水平增加6 - 14倍。所有这些参数在72小时时恢复到基线水平。给予挑战后,d(2)-γ-T等效物的总尿排泄量约为7mg。γ-T的基线水平与补充后血浆中(d(0) + d(2)) - γ - T和γ-CEHC水平的升高呈正相关,但与尿液中(d(0) + d(2))-γ-CEHC水平呈负相关。补充100mgγ-TAC对血浆中α-T的浓度以及α-T相关代谢产物的形成和排泄影响极小。
摄入100mg的γ-TAC会使γ-T的血浆浓度短暂升高,因为它会持续分解代谢为CEHC,而不会显著影响预先存在的血浆γ-T池,也不会影响α-T的浓度和代谢。这些途径似乎受到严格调控,很可能是为了保持α-T与γ-T以及γ-CEHC与α-CEHC的高稳态血液比率。